Opens in a new tab
Healthcare Market Research Worldwide

Diffuse Large B-cell Lymphoma

Track treatment pathways, prescriber behavior and market dynamics in Diffuse large B-cell lymphoma (DLBCL), powered by real-world data, not assumptions.
Talk to an Expert
Why Therapy Intelligence™

The intelligence your teams actually need

Leveraging real-world patient data, our Therapy Intelligence™ solution goes beyond syndicated studies to deliver fast, robust, multi-country insights, whether used standalone or integrated with custom methodologies.
Ready in days

Data already collected. Access study extracts immediately, full data within days of your request.

Physician-led study design

Every study is co-designed with leading physicians in the therapeutic area. Rigorous methodology, clinically grounded.

Fully customizable analysis

The analysis is yours to shape. Tell us what questions matter to your strategy and we tailor the outputs accordingly.

Trusted by Top 15 Global Pharma Companies
Study Scope

The questions that matter in Diffuse Large B-cell Lymphoma

Our DLBCL Therapy Intelligence covers real-world treatment response and outcomes from upfront therapy through relapsed/refractory disease, including the impact of molecular subtypes and high-risk genetic subsets, what happens when patients do not achieve complete remission, the effect of prior rituximab exposure on salvage treatment, and the management of CAR-T and bispecific toxicities and CAR-T resistance. Modules can be tailored to your research questions.

1+
HCP interviewed
1
Countries covered
1k+
PRFs
How are molecular subtypes like GCB vs. ABC DLBCL driving differences in real-world treatment response?
How are high-risk genetic subsets like double-hit or triple-hit lymphoma being identified and managed?
How often do patients fail to achieve complete remission with upfront therapy, and what happens next?
How is prior rituximab exposure affecting the efficacy of subsequent anti-CD20 salvage treatments?
How are severe toxicities from CAR-T and bispecific therapies being managed in real-world practice?
How is CAR-T resistance, through antigen loss or T-cell exhaustion, affecting long-term outcomes?
Clinical Truth to Business Impact

From the lab to the boardroom

Growth Lever
Message
Application
Identify growth opportunities
Untapped patient segments, under-treated eligible pools and white-space opportunities
e.g. Under-treated relapsed/refractory pools not yet referred for CAR-T
Refine your positioning
See where the brand wins, where it stalls and how the competitive frame should evolve
e.g. Positioning versus emerging bispecific antibodies in later lines
Activate the right HCPs
Identify over- and under-performing physicians and unlock adoption opportunities
e.g. Oncologist segments slower to refer patients for CAR-T evaluation
Anticipate market evolution
Track launches, sequence changes, access shifts and new behaviors earlier
e.g. Shifting treatment sequencing as bispecifics move into earlier lines

Let's Talk

Paul Taylor
Strategic Partnership Director
Manuel Guzman Martin
Vice President Commercial Global
Mélanie Marrot, PhD
Vice President Commercial France
Contact our Experts
Back

Paul Taylor

Strategic Partnership Director

Paul brings over 20 years of pharmaceutical business development and client partnership experience across Europe, the US, Japan, and Latin America. He has a long term exposure to longitudinal hospital data and strong expertise in oncology, neurology, and other complex and emerging therapeutic areas.

At APLUSA, Paul focuses on building and growing strategic client collaborations.. He works closely with clients, external partners and internal teams to create long-term value, unlock new mutually beneficial opportunities, and ensure joint initiatives translate into concrete business impact for clients.

Most people we know have been affected by cancer or a life-changing medical condition in some way. By working collaboratively and combining our efforts, we can improve patient outcomes, and we must all believe in our ability to make a meaningful difference for patients. Paul has a passion for sport (Cricket) and travel as well as trying to play golf!

Back

Manuel Guzman Martin

Vice President Commercial Global

Manuel is a senior healthcare market research and commercial leader with strong expertise in client engagement and growth. He has built his career across pharma, biotech and medtech, with a particular focus on oncology, immunology and cardio-metabolic diseases. His background spans senior roles in global consulting as well as in-house positions, giving him a grounded view of both strategy and execution.

At APLUSA, Manuel leads the global commercial organization, partnering with Key Account Directors, Customer Success Managers and Strategic Partnership Directors to drive sustainable growth by staying close to client needs and market dynamics. He works with teams to translate complex business and scientific questions into clear, decision-enabling strategies, while building long-term, trusted partnerships and ensuring high levels of client satisfaction. He also plays a key role in shaping APLUSA’s commercial strategy and international expansion.

Driven by curiosity and collaboration, Manuel is motivated by helping teams and clients turn robust insights into confident decisions that make a real impact.

Back

Mélanie Marrot, PhD

Vice President Commercial France

Mélanie is a PhD-trained scientist who moved from academic research into healthcare marketing and has built more than 15 years of experience in medical market research. She combines strong analytical depth with a practical understanding of how pharma markets work, and is known for anticipating client needs and turning complex data into clear, decision-ready insights across a wide range of therapeutic areas.

At APLUSA, Mélanie is a key client-facing leader for France, partnering closely with teams to design the right methodologies, guide studies from proposal to recommendation, and ensure consistently high scientific and strategic standards. She plays an active role in strengthening long-term client relationships, leading high-volume programs smoothly, and bringing added value through sharp interpretation and tailored recommendations.

A mountaineer at heart, Mélanie builds client relationships as true partnerships, grounded in trust, collaboration, and shared ambition, bringing the resilience, discipline, and adaptability of the mountains to every project.

Back

Complete My Registration

Diffuse Large B-cell Lymphoma
Back

Share Your Feedback

Diffuse Large B-cell Lymphoma
Back

Cancel Your Registration

Diffuse Large B-cell Lymphoma
Back

Add to Your Calendar

Diffuse Large B-cell Lymphoma

Google Calendar icon showing date 31
Google Calendar
Microsoft Power Automate and Outlook logos
Outlook (Personal)
Solid orange background with thin black bottom edge
Outlook (Professional)
Back

Talk to a Strategic Expert

Schedule your session to gain clear, actionable next steps and expert guidance tailored to your strategic goals.
Back

Talk to an Expert

Do you have a specific question, want to discuss a project, or just want to find out more details about one of our services?
Back

Choose Language

Back

Don’t Miss Our Next Academy Session

Get updates on upcoming training in healthcare market research and improve how your team manages insights.
Back

Don’t Miss Our Next Briefing

Join our briefings to connect and explore hot topics in pharma. Sign up to get notified about new sessions.
Back

Back

Subscribe to Our Newsletter

Stay ahead with impactful insights, the latest news from APLUSA, and updates on our events, both the ones we attend and the ones we host.